Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: A systematic review

Vaccine

Volumn 31, Issue 1, 2012, Pages 96-108

  Ozawa, Sachiko ^a   Mirelman, Andrew ^a   Stack, Meghan L ^a   Walker, Damian G ^b   Levine, Orin S ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

Benefits; Cost effectiveness; DALY; Economic evaluation; Systematic review; Vaccine

Indexed keywords

VACCINE;

ARTICLE; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; EPIDEMIC; GROSS NATIONAL PRODUCT; HEALTH CARE COST; HUMAN; PRIORITY JOURNAL; PRODUCTIVITY; SYSTEMATIC REVIEW; VACCINATION;

COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; HUMANS; QUALITY-ADJUSTED LIFE YEARS; VACCINATION;

EID: 84870500650     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.10.103     Document Type: Article

References (119)

1. John T.J., Samuel R. Herd immunity and herd effect: new insights and definitions. Eur J Epidemiol 2000, 16(7):601-606.
2. Evans D., Edejer T., Chisholm D., Stanciole A. WHO guide to identifying the economic consequences of disease and injury 2009, Department of Health Systems Financing, Health Systems and Services, World Health Organization, Geneva.
3. Ehreth J. The value of vaccination: a global perspective. Vaccine 2003, 21(27-30):4105-4117.
4. Bloom D., Cannning D., Jamison D. Health, wealth and welfare. Finance Dev 2004, March:10-15.
5. Shearley A.E. The societal value of vaccination in developing countries. Vaccine 1999, 17(October (Suppl. 3)):S109-S112.
6. Elias C. The Decade of Vaccines Collaboration: developing a global roadmap for saving lives. Expert Rev Vaccines 2011, 10(November (11)):1493-1495.
7. Barnighausen T., Bloom D.E., Canning D., Friedman A., Levine O.S., O'Brien J., et al. Rethinking the benefits and costs of childhood vaccination: the example of the Haemophilus influenzae type b vaccine. Vaccine 2011, 29(March (13)):2371-2380.
8. Barnighausen T., Bloom D.E., Canning D., O'Brien J. Accounting for the full benefits of childhood vaccination in South Africa. S Afr Med J 2008, 98(November (11)). 842, 4-6.
9. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6(July (7)):e1000097.
10. Aballea S., Chancellor J., Martin M., Wutzler P., Carrat F., Gasparini R., et al. The cost-effectiveness of influenza vaccination for people aged 50-64 years: an international model. Value Health 2007, 10(March-April (2)):98-116.
11. Acharya A., Diaz-Ortega J.L., Tambini G., de Quadros C., Arita I. Cost-effectiveness of measles elimination in Latin America and the Caribbean: a prospective analysis. Vaccine 2002, 20(27-28):3332-3341.
12. Aggarwal R. Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model. J Hepatol 2003, 38(2):215-222.
13. Akumu A.O., English M., Scott J.A., Griffiths U.K. Economic evaluation of delivering Haemophilus influenzae type b vaccine in routine immunization services in Kenya. Bull World Health Organ 2007, 85(July (7)):511-518.
14. Amirfar S., Hollenberg J.P., Abdool Karim S.S. Modeling the impact of a partially effective HIV vaccine on HIV infection and death among women and infants in South Africa. J Acquir Immune Defic Syndr 2006, 43(October (2)):219-225.
15. Apisarnthanarak A., Puthavathana P., Kitphati R., Auewarakul P., Mundy L. Outbreaks of Influenza A among nonvaccinated healthcare workers: implications for resource-limited settings. Infect Control Hosp Epidemiol 2008, 29(8):777-780.
16. Atherly D., Dreibelbis R., Parashar Umesh D., Levin C., Wecker J., Rheingans Richard D. Rotavirus vaccination: cost effectiveness and impact on child mortality in developing countries. J Infect Dis 2009, 200(s1):S28-S38.
17. Bahl R., Sinha A., Poulos C., Whittington D., Sazawal S., Kumar R., et al. Costs of illness due to typhoid fever in an Indian urban slum community: implications for vaccination policy. J Health Popul Nutr 2004, 22(September (3)):304-310.
18. Bawah A.A., Phillips J.F., Adjuik M., Vaughan-Smith M., Macleod B., Binka F.N. The impact of immunization on the association between poverty and child survival: evidence from Kassena-Nankana District of northern Ghana. Scand J Public Health 2010, 38(February (1)):95-103.
19. Berndt E.R., Glennerster R., Kremer M.R., Lee J., Levine R., Weizsäcker G., et al. Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness. Health Econ 2007, 16(5):491-511.
20. Berry S.A., Johns B., Shih C., Berry A.A., Walker D.G. The cost-effectiveness of rotavirus vaccination in Malawi. J Infect Dis 2010, 202(Suppl.):S108-S115.
21. Bishai D., Johns B., Lefevre A., Nair D. Cost effectiveness of measles eradication 2010, Johns Hopkins Bloomberg School of Public Health, Baltimore.
22. Bishai D., Lin M.K., Kiyonga C.W. Modeling the economic benefits of an AIDS vaccine. Vaccine 2001, 20(November (3-4)):526-531.
23. Bloom D., Canning D., Seiguer E. The effect of vaccination on children's physical and cognitive development in the Phillipines. Program on the global demography of aging 2010, Harvard School of Public Health, Boston, p. 1-16.
24. Bloom D., Canning D., Weston M. The value of vaccination. World Econ 2005, 6(3):15-39.
25. Broughton E.I. Economic evaluation of Haemophilus influenzae type B vaccination in Indonesia: a cost-effectiveness analysis. J Public Health 2007, 29(4):441-448.
26. Centenari C., Gurgel R.Q., Bohland A.K., Oliveira D.M., Faragher B., Cuevas L.E. Rotavirus vaccination in northeast Brazil: a laudable intervention, but can it lead to cost-savings?. Vaccine 2010, 28(June (25)):4162-4168.
27. Chan P.W., Abdel-Latif M.E. Cost of hospitalization for respiratory syncytial virus chest infection and implications for passive immunization strategies in a developing nation. Acta Paediatr 2003, 92(April (4)):481-485.
28. Chandrasena N., Rajindrajith S., Ahmed K., Pathmeswaran A., Nakagomi O. Hospital-based study of the severity and economic burden associated with rotavirus diarrhea in Sri Lanka. J Pediatr Infect Dis 2009, 4(4):379-386.
29. Chotivitayatarakorn P., Poovorawan Y. Cost-effectiveness of rotavirus vaccination as part of the national immunization program for Thai children. Southeast Asian J Trop Med Public Health 2010, 41(January (1)):114-125.
30. Clark A.D., Walker D.G., Mosqueira N.R., Penny M.E., Lanata C.F., Fox-Rushby J., et al. Cost-effectiveness of rotavirus vaccination in Peru. J Infect Dis 2009, 200(Suppl. 1):S114-S124.
31. Colantonio L., Gomez J.A., Demarteau N., Standaert B., Pichon-Riviere A., Augustovski F. Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries. Vaccine 2009, 27(September (40)):5519-5529.
32. Constenla D., Velázquez F.R., Rheingans R.D., Antil L., Cervantes Y. Economic impact of a rotavirus vaccination program in Mexico. Rev Panam Salud Pública 2009, 25(6):481-490.
33. Constenla D.O. Economic impact of pneumococcal conjugate vaccination in Brazil, Chile, and Uruguay. Rev Panam Salud Pública 2008, 24(2):101-112.
34. Constenla D.O., Linhares A.C., Rheingans R.D., Antil L.R., Waldman E.A., da Silva L.J. Economic impact of a rotavirus vaccine in Brazil. J Health Popul Nutr 2008, 26(4):388-396.
35. Cook J., Jeuland M., Maskery B., Lauria D., Sur D., Clemens J., et al. Using private demand studies to calculate socially optimal vaccine subsidies in developing countries. J Policy Anal Manage 2009, 28(1):6-28.
36. Cook J., Jeuland M., Whittington D., Poulos C., Clemens J., Sur D., et al. The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries. Vaccine 2008, 26(November (50)):6305-6316.
37. Cook J., Sur D., Clemens J., Whittington D. Evaluating investments in typhoid vaccines in two slums in Kolkata, India. J Health Popul Nutr 2009, 27(December (6)):711-724.
38. Cropper M., Haile M., Lampietti J., Poulos C., Whittington D. The demand for a malaria vaccine: evidence from Ethiopia. J Dev Econ 2004, 75:303-318.
39. Dayan G.H., Cairns L., Sangrujee N., Mtonga A., Nguyen V., Strebel P. Cost-effectiveness of three different vaccination strategies against measles in Zambian children. Vaccine 2004, 22(3-4):475-484.
40. De la Hoz F., Alvis N., Narváez J., Cediel N., Gamboa O., Velandia M. Potential epidemiological and economical impact of two rotavirus vaccines in Colombia. Vaccine 2010, 28(22):3856-3864.
41. de Soarez P.C., Valentim J., Sartori A.M., Novaes H.M. Cost-effectiveness analysis of routine rotavirus vaccination in Brazil. Rev Panam Salud Publica 2008, 23(April (4)):221-230.
42. Diaz M., Kim J.J., Albero G., de Sanjosé S., Clifford G., Bosch F.X., et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer 2008, 99(2):230-238.
43. Ding D., Kilgore P., Clemens J., Wei L., Zhi-Yi X. Cost-effectiveness of routine immunization to control Japanese encephalitis in Shanghai, China. Bull World Health Organ 2003, 81(5):334-342.
44. Duintjer Tebbens R.J., Pallansch M.A., Cochi S.L., Wassilak S.G.F., Linkins J., Sutter R.W., et al. Economic analysis of the global polio eradication initiative. Vaccine 2010, 29(2):43-334.
45. Edejer T.T.T. Cost effectiveness analysis of strategies for child health in developing countries. Br Med J 2005, 331(7526):1177-1180.
46. Ehrenkranz P., Lanata C.F., Penny M.E., Salazar-Lindo E., Glass R.I. Rotavirus diarrhea disease burden in Peru: the need for a rotavirus vaccine and its potential cost savings. Rev Panam Salud Publica 2001, 10(October (4)):240-248.
47. Ellis A., Ruttimann R.W., Jacobs R.J., Meyerhoff A.S., Innis B.L. Cost-effectiveness of childhood hepatitis A vaccination in Argentina: a second dose is warranted. Rev Panam Salud Publica 2007, 21(June (6)):345-356.
48. Ezat W.P., Aljunid S. Cost-effectiveness of HPV vaccination in the prevention of cervical cancer in Malaysia. Asian Pac J Cancer Prev 2010, 11(1):79-90.
49. Fischer T.K., Anh D.D., Antil L., Cat N.D.L., Kilgore P.E., Thiem V.D., et al. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. J Infect Dis 2005, 192(10):1720-1726.
50. Flem E.T., Latipov R., Nurmatov Z.S., Xue Y., Kasymbekova K.T., Rheingans R.D. Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in Kyrgyzstan. J Infect Dis 2009, 200(November (Suppl. 1)):S195-S202.
51. Gessner B.D., Sedyaningsih E.R., Griffiths U.K., Sutanto A., Linehan M., Mercer D., et al. Vaccine-preventable haemophilus influenza type B disease burden and cost-effectiveness of infant vaccination in Indonesia. Pediatr Infect Dis J 2008, 27(5):438-443.
52. Giglio N.D., Cane A.D., Micone P., Gentile A. Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina. Vaccine 2010, 28(March (11)):2302-2310.
53. Goldie S.J., Kim J.J., Kobus K., Goldhaber-Fiebert J.D., Salomon J., O'Shea M.K., et al. Cost-effectiveness of HPV 16,18 vaccination in Brazil. Vaccine 2007, 25(August (33)):6257-6270.
54. Goldie S.J., O'Shea M., Campos N.G., Diaz M., Sweet S., Kim S.-Y. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 2008, 26(32):4080-4093.
55. Goldie S.J., O'Shea M., Diaz M., Kim S.-Y. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications. Reprod Health Matters 2008, 16(32):86-96.
56. Griffiths U.K., Botham L., Schoub B.D. The cost-effectiveness of alternative polio immunization policies in South Africa. Vaccine 2006, 24(July (29-30)):5670-5678.
57. Griffiths U.K., Hutton G., Das Dores Pascoal E. The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique. Health Policy Plan 2005, 20(January (1)):50-59.
58. Heinzen R.R., Bridges J.F. Comparison of four contingent valuation methods to estimate the economic value of a pneumococcal vaccine in Bangladesh. Int J Technol Assess Health Care 2008, 24(Fall (4)):481-487.
59. Hussain H., Waters H., Omer S.B., Khan A., Baig I.Y., Mistry R., et al. The cost of treatment for child pneumonias and meningitis in the Northern Areas of Pakistan. Int J Health Plann Manage 2006, 21(July-September (3)):38-229.
60. Hutton D.W., So S.K., Brandeau M.L. Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China. Hepatology 2010, 51(February (2)):405-414.
61. Insinga R.P., Dasbach E.J., Elbasha E.H., Puig A., Reynales-Shigematsu L.M. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 2007, 26(December (1)):128-139.
62. Isakbaeva E.T., Musabaev E., Antil L., Rheingans R., Juraev R., Glass R.I., et al. Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine. Vaccine 2007, 25(January (2)):373-380.
63. Islam Z., Maskery B., Nyamete A., Horowitz M.S., Yunus M., Whittington D. Private demand for cholera vaccines in rural Matlab, Bangladesh. Health Policy 2008, 85(February (2)):184-195.
64. Jeuland M., Cook J., Poulos C., Clemens J., Whittington D. Cost-effectiveness of new-generation oral cholera vaccines: a multisite analysis. Value Health 2009, 12(6):899-908.
65. Jeuland M., Whittington D. Cost-benefit comparisons of investments in improved water supply and cholera vaccination programs. Vaccine 2009, 27(23):3109-3120.
66. Jeuland M., Lucas M., Clemens J., Whittington D. Estimating the private benefits of vaccination against cholera in Beira, Mozambique: a travel cost approach. J Dev Econ 2010, 91:310-322.
67. Khan M.M. Economics of polio vaccination in the post-eradication era: should OPV-using countries adopt IPV?. Vaccine 2008, 26(16):2034-2040.
68. Kim D., Canh do G., Poulos C., Thoa le T.K., Cook J., Hoa N.T., et al. Private demand for cholera vaccines in Hue, Vietnam. Value Health 2008, 11(January-February (1)):28-119.
69. Kim J.J., Kobus K.E., Diaz M., O'Shea M., Van Minh H., Goldie S.J. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy. Vaccine 2008, 26(July (32)):4015-4024.
70. Kim S.-Y., Goldie S.J., Salomon J.A. Cost-effectiveness of rotavirus vaccination in Vietnam. BMC Public Health 2009, 9(1):29.
71. Kim S.-Y., Lee G., Goldie S.J. Economic evaluation of pneumococcal conjugate vaccination in The Gambia. BMC Infect Dis 2010, 10:260.
72. Kim S.-Y., Salomon J., Goldie S. Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves. Bull World Health Organ 2007, 85(11):833-842.
73. Kim S.-Y., Sweet S., Slichter D., Goldie S.J. Health and economic impact of rotavirus vaccination in GAVI-eligible countries. BMC Public Health 2010, 10:253.
74. Lopez E., Debbag R., Coudeville L., Baron-Papillon F., Armoni J. The cost-effectiveness of universal vaccination of children against hepatitis A in Argentina: results of a dynamic health-economic analysis. J Gastroenterol 2007, 42(February (2)):152-160.
75. Lucas M.E., Jeuland M., Deen J., Lazaro N., MacMahon M., Nyamete A., et al. Private demand for cholera vaccines in Beira, Mozambique. Vaccine 2007, 25(March (14)):2599-2609.
76. Massad E., Coutinho F.A., Chaib E., Burattini M.N. Cost-effectiveness analysis of a hypothetical hepatitis C vaccine compared to antiviral therapy. Epidemiol Infect 2009, 137(February (2)):241-249.
77. Meij J.J., de Craen A.J., Agana J., Plug D., Westendorp R.G. Low-cost interventions accelerate epidemiological transition in Upper East Ghana. Trans R Soc Trop Med Hyg 2009, 103(February (2)):173-178.
78. Novaes H., Luna E., Goldbaum M., Kilsztajn S., Rossbach A., de la Rocha Carvalheiro J. The potential demand for an HIV/AIDS vaccine in Brazil. World Bank policy research working paper 2940 2002, The World Bank, Washington, DC, p. 1-30.
79. Ono S., Kurotaki T., Nakasone T., Honda M., Boon-Long J., Sawanpanyalert P., et al. Cost-effectiveness analysis of antiretroviral drug treatment and HIV-1 vaccination in Thailand. Jpn J Infect Dis 2006, 59:168-173.
80. Ortega O., El-Sayed N., Sanders J.W., Abd-Rabou Z., Antil L., Bresee J., et al. Cost-benefit analysis of a rotavirus immunization program in the Arab Republic of Egypt. J Infect Dis 2009, 200(November (Suppl. 1)):S92-S98.
81. Palanca-Tan R. The demand for a dengue vaccine: a contingent valuation survey in Metro Manila. Vaccine 2008, 26(February (7)):914-923.
82. Parent du Châtelet I., Gessner B.D., da Silva A. Comparison of cost-effectiveness of preventive and reactive mass immunization campaigns against meningococcal meningitis in West Africa: a theoretical modeling analysis. Vaccine 2001, 19(25-26):3420-3431.
83. Platonov A.E., Griffiths U.K., Voeykova M.V., Platonova O.V., Shakhanina I.L., Chistyakova G.G., et al. Economic evaluation of Haemophilus influenzae type b vaccination in Moscow, Russian Federation. Vaccine 2006, 24(March (13)):2367-2376.
84. Podewils L.J., Antil L., Hummelman E., Bresee J., Parashar U.D., Rheingans R. Projected cost-effectiveness of rotavirus vaccination for children in Asia. J Infect Dis 2005, 192(Suppl. 1):S133-S145.
85. Poulos C., Bahl R., Whittington D., Bhan M.K., Clemens J.D., Acosta C.J. A cost-benefit analysis of typhoid fever immunization programmes in an Indian urban slum community. J Health Popul Nutr 2004, 22(3):311-321.
86. Prakash C. Crucial factors that influence cost-effectiveness of universal hepatitis B immunization in India. Int J Technol Assess Health Care 2003, 19(Winter (1)):28-40.
87. Quezada A., Baron-Papillon F., Coudeville L., Maggi L. Universal vaccination of children against hepatitis A in Chile: a cost-effectiveness study. Rev Panam Salud Publica 2008, 23(May (5)):303-312.
88. Reynales-Shigematsu L.M., Rodrigues E.R., Lazcano-Ponce E. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico. Arch Med Res 2009, 40(6):503-513.
89. Rheingans Richard D., Antil L., Dreibelbis R., Podewils Laura J., Bresee Joseph S., Parashar Umesh D. Economic costs of rotavirus gastroenteritis and cost effectiveness of vaccination in developing countries. J Infect Dis 2009, 200(s1):S16-S27.
90. Rheingans R.D., Constenla D., Antil L., Innis B.L., Breuer T. Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries. Rev Panam Salud Publica 2007, 21(April (4)):205-216.
91. Rose J., Hawthorn R.L., Watts B., Singer M.E. Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis. Br Med J 2009, 339:b3653.
92. Sauerborn R., Gbangou A., Dong H., Przyborski J.M., Lanzer M. Willingness to pay for hypothetical malaria vaccines in rural Burkina Faso. Scand J Public Health 2005, 33(2):146-150.
93. Simmerman J.M., Lertiendumrong J., Dowell S.F., Uyeki T., Olsen S.J., Chittaganpitch M., et al. The cost of influenza in Thailand. Vaccine 2006, 24(May (20)):4417-4426.
94. Sinanovic E., Moodley J., Barone M.A., Mall S., Cleary S., Harries J. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa. Vaccine 2009, 27(October (44)):6196-6202.
95. Sinha A., Constenla D., Valencia J.E., O'Loughlin R., Gomez E., de la Hoz F., et al. Cost-effectiveness of pneumococcal conjugate vaccination in Latin America and the Caribbean: a regional analysis. Rev Panam Salud Pública 2008, 24(5):304-313.
96. Sinha A., Levine O., Knoll M.D., Muhib F., Lieu T.A. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet 2007, 369(9559):389-396.
97. Soogarun S., Wiwanitkit V. Vaccinating Thai adolescents against hepatitis A: is it cost-effective?. Southeast Asian J Trop Med Public Health 2002, 33(Suppl. 3):8-145.
98. Taal M.W., van Zyl-Smit R. Cost-effectiveness of hepatitis B vaccination in haemodialysis patients. S Afr Med J 2001, 91(April (4)):340-344.
99. Tate J.E., Rheingans R.D., O'Reilly C.E., Obonyo B., Burton D.C., Tornheim J.A., et al. Rotavirus disease burden and impact and cost-effectiveness of a rotavirus vaccination program in Kenya. J Infect Dis 2009, 200(Suppl. 1):S76-S84.
100. Tediosi F., Hutton G., Maire N., Smith T.A., Ross A., Tanner M. Predicting the cost-effectiveness of introducing a pre-erythrocytic malaria vaccine into the expanded program on immunization in Tanzania. Am J Trop Med Hyg 2006, 75(2 Suppl.):131-143.
101. Thompson K.M., Tebbens R.J.D. Eradication versus control for poliomyelitis: an economic analysis. Lancet 2007, 369(9570):1363-1371.
102. Touch S., Suraratdecha C., Samnang C., Heng S., Gazley L., Huch C., et al. A cost-effectiveness analysis of Japanese encephalitis vaccine in Cambodia. Vaccine 2010, 28(29):4593-4599.
103. Udezi W.A., Usifoh C.O., Ihimekpen O.O. Willingness to pay for three hypothetical malaria vaccines in Nigeria. Clin Ther 2010, 32(August (8)):1533-1544.
104. Uzicanin A., Zhou F., Eggers R., Webb E., Strebel P. Economic analysis of the 1996-1997 mass measles immunization campaigns in South Africa. Vaccine 2004, 22(September (25-26)):3419-3426.
105. Valencia-Mendoza A., Bertozzi S.M., Gutierrez J.-P., Itzler R. Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico. BMC Infect Dis 2008, 8(1):103.
106. Valentim J., Sartori A.M., de Soarez P.C., Amaku M., Azevedo R.S., Novaes H.M. Cost-effectiveness analysis of universal childhood vaccination against varicella in Brazil. Vaccine 2008, 26(November (49)):6281-6291.
107. Valenzuela M.T., Jacobs R.J., Arteaga O., Navarrete M.S., Meyerhoff A.S., Innis B.L. Cost-effectiveness of universal childhood hepatitis A vaccination in Chile. Vaccine 2005, 23(July (32)):4110-4119.
108. Vespa G., Constenla D.O., Pepe C., Safadi M.A., Berezin E., de Moraes J.C., et al. Estimating the cost-effectiveness of pneumococcal conjugate vaccination in Brazil. Rev Panam Salud Pública 2009, 26(6):518-528.
109. Vimolket T., Poovorawan Y. An economic evaluation of universal infant vaccination strategies against hepatitis B in Thailand: an analytic decision approach to cost-effectiveness. Southeast Asian J Trop Med Public Health 2005, 36(May (3)):693-699.
110. Wang X.Y., Riewpaiboon A., von Seidlein L., Chen X.B., Kilgore P.E., Ma J.C., et al. Potential cost-effectiveness of a rotavirus immunization program in rural China. Clin Infect Dis 2009, 49(October (8)):1202-1210.
111. Whittington D., Matsui-Santana O., Freiberger J.J., Van Houtven G., Pattanayak S. Private demand for a HIV/AIDS vaccine: evidence from Guadalajara, Mexico. Vaccine 2002, 20(June (19-20)):2585-2591.
112. Whittington D., Suraratdecha C., Poulos C., Ainsworth M., Prabhu V., Tangcharoensathien V. Household demand for preventive HIV/AIDS vaccines in Thailand: do husbands' and wives' preferences differ?. Value Health 2008, 11(September-October (5)):965-974.
113. Whittington D., Sur D., Cook J., Chatterjee S., Maskery B., Lahiri M., et al. Rethinking cholera and typhoid vaccination policies for the poor: private demand in Kolkata, India. World Dev 2009, 37(2):399-409.
114. Wilopo S.A., Kilgore P., Kosen S., Soenarto Y., Aminah S., Cahyono A., et al. Economic evaluation of a routine rotavirus vaccination programme in Indonesia. Vaccine 2009, 27(November (Suppl. 5)):F67-F74.
115. Wongsurakiat P., Lertakyamanee J., Maranetra K.N., Jongriratanakul S., Sangkaew S. Economic evaluation of influenza vaccination in Thai chronic obstructive pulmonary disease patients. J Med Assoc Thai 2003, 86(June (6)):497-508.
116. Zahdi M.R., Maluf I., Maluf E.M. Hepatitis A: the costs and benefits of the disease prevention by vaccine, Parana, Brazil. Braz J Infect Dis 2009, 13(August (4)):257-261.
117. Zhuang G.H., Pan X.J., Wang X.L. A cost-effectiveness analysis of universal childhood hepatitis A vaccination in China. Vaccine 2008, 26(August (35)):4608-4616.
118. Ozawa S., Stack M.L., Bishai D.M., Mirelman A., Friberg I.K., Niessen L., et al. During the 'Decade of Vaccines,' the lives of 6.4 million children valued at $231 billion could be saved. Health Aff (Millwood) 2011, 30(June (6)):1010-1020.
119. Stack M.L., Ozawa S., Bishai D.M., Mirelman A., Tam Y., Niessen L., et al. Estimated economic benefits during the 'Decade of Vaccines' include treatment savings, gains in labor productivity. Health Aff (Millwood) 2011, 30(June (6)):1021-1028.